High Affinity Antibodies Against Staphylococcal Enterotoxin B
Author Information
Author(s): Brian Drozdowski, Yuhong Zhou, Brad Kline, Jared Spidel, Yin Yin Chan, Earl Albone, Howard Turchin, Qimin Chao, Marianne Henry, Jacqueline Balogach, Eric Routhier, Sina Bavari, Nicholas C Nicolaides, Philip M Sass, Luigi Grasso
Primary Institution: Morphotek Inc.
Hypothesis
Can human monoclonal antibodies effectively neutralize staphylococcal enterotoxin B (SEB) in vitro and in vivo?
Conclusion
The study successfully generated high-affinity SEB-specific antibodies that can neutralize SEB in vitro and protect mice from lethal doses of SEB in vivo.
Supporting Evidence
- HuMAb-154 was capable of neutralizing up to 100 μg of SEB challenge, protecting mice from death.
- In vitro, HuMAbs inhibited SEB-induced secretion of proinflammatory cytokines by human lymphocytes.
- The study demonstrated that HuMAb-154 could be administered after SEB challenge and still provide significant protection.
Takeaway
Scientists created special antibodies that can stop a harmful toxin from making people sick, and they tested these antibodies in mice to see if they work.
Methodology
Human B-cell hybridomas were generated to produce HuMAbs, which were then screened for specificity and potency against SEB in vitro and in vivo.
Potential Biases
Potential bias in the selection of hybridomas based on their reactivity to SEB.
Limitations
The study primarily used mouse models, which may not fully replicate human responses to SEB exposure.
Participant Demographics
Healthy individuals provided blood samples for B-cell isolation.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website